Skip to main content
SpringerLink
Log in

The Role of 18F-FDG-PET in the Local/Regional Evaluation of Women with Breast Cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose. In women with breast cancer, knowledge of the local/regional extent of the tumor is essential for staging, treatment planning, monitoring response to therapy, and follow-up. Positron emission tomography (PET) is an important imaging test which can detect tumor at multiple sites in women with breast cancer. We compared the ability of PET to provide a comprehensive view of the local/regional extent of tumor in women with stage I, II and stage III, IV breast cancer.

Materials and methods. Forty-six women with breast cancer underwent PET using 18F-FDG. 18FDG uptake in the breast primary tumor, associated skin, axillary and internal mammary lymph nodes, and the contralateral breast was determined qualitatively, and correlated with histologic, clinical and radiographic findings.

Results. Twenty-four patients were premenopausal and 22 were postmenopausal, with the following distribution according to clinical stage: stage I – 2 patients, stage II – 16, stage III – 16, stage IV – 12 patients. Among stage I, II patients, the sensitivity for detection of the primary tumor was 83.3%, and for detection of axillary lymph node metastases was 42.9%. 18FDG-PET was negative for the breast skin, contralateral breast, and internal mammary lymph nodes in all stage I, II patients, in agreement with clinical and radiographic findings. Among 28 stage III, IV patients, the sensitivity of 18FDG-PET for detection of the primary tumor was 90.5%, and for detection of axillary lymph node metastases 83.3%. Fourteen patients had clinically advanced changes in the skin, and the sensitivity of PET for detection of skin changes was 76.9%. 18FDG-PET was positive in the internal mammary lymph nodes in 25.0%, and negative in the contralateral breast in all patients with stage III, IV breast cancer. 18FDG-PET was studied in 10 patients following neoadjuvant chemotherapy, and showed a strong correlation with clinical response, and with clinical and pathological findings post-treatment at multiple local/regional sites.

Conclusion. 18FDG-PET can provide a comprehensive image of local/regional tumor in women with breast cancer. 18FDG-PET may play a greater role in women with stage III, IV breast cancer because of increased sensitivity and the increased involvement of multiple local/regional sites with tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer Statistics 2000. CA: A Cancer J Clinicians 50: 7–33, 2000

    Google Scholar 

  2. Hata Y, Ogawa Y, Nishioka A, Inomata T, Yoshida S: Thin section computed tomography in the prone position for detec-tion of axillary lymph node metastases in breast cancer. Oncol Rep 5: 1403–1406, 1998

    PubMed  Google Scholar 

  3. Lernevall A: Imaging of axillary lymph nodes. Acta Oncol 39: 277–281, 2000

    PubMed  Google Scholar 

  4. Warburg O: The Metabolism of Tumors. Richard R. Smith, Inc.; 1931.

  5. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP: Metabolic trapping as a principle of ora-diopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 19: 1154–1161, 1978

    PubMed  Google Scholar 

  6. Adler LP, Crowe JP, Al-Kaisi NK, Sunshine JL: Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiol 187: 743–750, 1993

    PubMed  Google Scholar 

  7. Tse NY, Hoh CK, Hawkins RA, Zinner MJ, Dahlbom M, Choi Y, Maddahi J, Brunicardi FC, Phelps ME, Glaspy JA: The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 216: 27–34, 1992

    PubMed  Google Scholar 

  8. Scheidhauer K, Scharl A, Pietrzyk U: Qualitative {18F} FDG positron emission tomography. Eur J Nucl Med 6: 618–623, 1996

    Google Scholar 

  9. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, Detert DD, Cutler PD, Katzenellenbogen JA, Welch MJ: Positron tomographic assessment of estro-gen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36: 1766–1774, 1995

    PubMed  Google Scholar 

  10. Bassa P, Inoue T, Wong FC, Korkmaz M, Yang DJ, Wong WH, Hicks KW, Buzdar AU, Podoloff DA: Evaluation of preoperative chemotherapy using PET with fluorine-18-Fluorodeoxyglucose in breast cancer. J Nucl Med 37: 931–938, 1996

    PubMed  Google Scholar 

  11. Avril N, Menzel M, Dose J, Schelling M, Weber W, Janicke F, Nathrath W, Schwaiger M: Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 42: 9–16, 2001

    PubMed  Google Scholar 

  12. Avril N, Dose J, Janicke F, Ziegler S, Romer W, Weber W, Herz M, Nathrath W, Graeff H, Schwaiger M: Assess-ment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radio-labeled 2-(Fluorine-18)-fluoro-2-deoxy-D-glucose. JNCI 88: 1204–1209, 1996

    PubMed  Google Scholar 

  13. Noh DY, Yun IJ, Kim JS, Kang HS, Lee DS, Chung JK, Lee MC, Youn YK, Oh SK, Choe KJ: Diagnostic value of positron emission tomography for detecting breast cancer. World J Surg 22: 223–228, 1998

    PubMed  Google Scholar 

  14. Adler LP, Faulhaber PF, Schnur KC, Al-Kasi NL, Shenk RR: Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiol 203: 323–327, 1997

    Google Scholar 

  15. Cook GJ, Houston S, Maisey MN, Fogelman I: Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16: 3375–3379, 1998

    PubMed  Google Scholar 

  16. Petren-Mallmin M, Andreasson I, Ljunggren O, Ahlstrom H, Bergh J, Antoni G, Langstrom B, Bergstrom M: Skeletal meta-stases from breast cancer: uptake of 18F-fluoride measured with positron emission tomography in correlation with CT. Skel Radiol 27: 72–76, 1998

    Google Scholar 

  17. Bender H, Kirst J, Palmedo H, Schomburg A, Wagner U, Ruhlmann J, Biersack HJ: Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 17: 1687–1692, 1997

    PubMed  Google Scholar 

  18. Jansson T, Westlin JE, Ahlstrom H, Langstrom B, Bergh J: Positron emission tomography studies in patients with loc-ally advanced and/or metastatic breast cancer: a method for early therapy evaluation. J Clin Oncol 13: 1470–1477, 1995

    PubMed  Google Scholar 

  19. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R: Metabolic monitoring of breast cancer chemohormonother-.146 apy using positron emission tomography: Initial evaluation. J Clin Oncol 11: 2101–2111, 1993

    PubMed  Google Scholar 

  20. Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D, Werner M, Dose J, Janicke F, Graeff H, Schwaiger M: Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18: 1689–1695, 2000

    PubMed  Google Scholar 

  21. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, Waikar S, Whitaker T, Ah-See AK, Eremin O, Heys SD, Gilbert FJ, Sharp PF: Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18: 1676–1688, 2000

    PubMed  Google Scholar 

  22. Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yageta H, Shishikura T, Imazeki K, Nakajima N: Pre-dicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer 82: 2227–2234, 1998

    PubMed  Google Scholar 

  23. Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A, Decise D, De Sanctis V, Greco M, Daidone MG, Bom-bardieri E: Association between [18F]fluorodeoxyglucose up-take and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 25: 1429–1434, 1998

    PubMed  Google Scholar 

  24. Eubank WB, Mankoff DA, Takasugi J, Vesselle H, Eary JF, Shanley TJ, Gralow JR, Charlop A, Ellis GK, Lindsley KL, Austin-Seymour MM, Funkhouser CP, Livingston RB: 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 19: 3516–3523, 2001

    PubMed  Google Scholar 

  25. The Breast Cancer Task Force Treatment Committee NCI National Cancer Institute: Breast cancer: Suggested protocol guidelines for combination chemotherapy trials and for combined modality trials. Washington, DC United States Department of Health, Education, and Welfare Publication 78–1192, 1978

    Google Scholar 

  26. Smith IC, Ogston KN, Whitford P, Smith FW, Sharp P, Norton M, Miller ID, Ah-See AK, Hays SD, Jibril JA, Eremin O: Staging of the axilla in breast cancer. Ann Surg 228: 220–227, 1998

    PubMed  Google Scholar 

  27. Edge SB, Hurd TC: Sentinel lymph node update: Breast cancer. Oncology 13: 213–218, 2001

    Google Scholar 

  28. Yang JH, Nam SJ, Lee TS, Lee HK, Jung SH, Kim BT: Comparison of intraoperative frozen section analysis of sen-tinel node with preoperative positron emission tomography in the diagnosis of axillary lymph node status in breast cancer patients. Jpn J Clin Oncol 31: 1–6, 2001

    PubMed  Google Scholar 

  29. Danforth DN, Zujewski J, O'Shaughnessy J, Riseberg D, Steinberg D, Steinberg SM, McAtee N, Noone M, Chow C, Chaudhry U, Lippman M, Jacobson J, Okunieff P, Cowan KH: Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer. Ann Surg Oncol 5: 150–158, 1998

    PubMed  Google Scholar 

  30. Julian TB, Patel N, Dusi D, Olson P, Nathan G, Jasnosz K, Isaacs G, Wolmark N: Sentinel lymph node biopsy after neo-adjuvant chemotherapy for breast cancer. Am J Surg 182: 407–410, 2001

    PubMed  Google Scholar 

  31. Haid A, Tausch C, Lang A, Lutz J, Fritzsche H, Peschina W, Breitfellner G, Sega W, Aufschnaiter M, Sturn H, Zimmermann G: Is sentinel lymph node biopsy reliable and in-dicated after preoperative chemotherapy in patients with breast carcinoma? Cancer 92: 1080–1084, 2001

    PubMed  Google Scholar 

  32. Nason KS, Anderson BO, Byrd DR, Dunnwald LK, Eary JF, Mankoff DA, Livingston R, Schmidt RA, Jewell KD, Yeung RS, Moe RE: Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 89: 2187–2194, 2000

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgery Branch, National Cancer Institute, Bethesda, MD

    David N. Danforth Jr.

  2. Nuclear Medicine Dept, Bethesda, MD

    Luigi Aloj, Jorge A. Carrasquillo, Stephen L. Bacharach, Millie Whatley, Barbara Galen & Ronald D. Neumann

  3. Diagnostic Radiology Department, Clinical Center, National Institutes of Health, Bethesda, MD

    Cathy Chow

  4. Medicine Branch, Bethesda, MD

    JoAnne Zujewski

  5. Laboratory of Pathology, National Cancer Institute, Bethesda, MD

    Maria Merino

Authors
  1. David N. Danforth Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luigi Aloj
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jorge A. Carrasquillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephen L. Bacharach
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cathy Chow
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. JoAnne Zujewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Millie Whatley
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Barbara Galen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Maria Merino
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ronald D. Neumann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Danforth, D.N., Aloj, L., Carrasquillo, J.A. et al. The Role of 18F-FDG-PET in the Local/Regional Evaluation of Women with Breast Cancer. Breast Cancer Res Treat 75, 135–146 (2002). https://doi.org/10.1023/A:1019664126220

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1019664126220

Search

Navigation